Fig. 2. Assessment of the efficacy of compounds (1 and 2) against P. berghei NK-65 infection in the mouse model; (A) the mean percentage parasitemia of treated group versus untreated ones on days 5, 8, and 15 post-treatment. The data represent means ± SD using five animals (n = 5) in each group; (B) the survival response of mice during blood-stage infection and mean survival time (MST) (in days) treated versus untreated ones; (C) efficacy of compound 1 at 50 mg kg−1 (i.p) against P. berghei liver stage infection was compared with control mice using unpaired t-test (P < 0.02); and (D). The survival analysis of mice in liver-stage infection was monitored for compound 2 until day 30 post-infection (n = 4 per group).
